| Literature DB >> 35478535 |
Ci Wu1,2, Xingshuang Ning3, Xi Chen3, Junfeng Ma2, Qun Zhao4, Li Zhao4, Guozhi Zhu4, Song Shi4.
Abstract
A simple, accurate, and highly sensitive analytical method was developed in this study for the determination of ten β-agonists and five β-blockers in milk. In this method, new adsorbent phosphonic acid-functionalized porous organic polymers were synthesized through a direct knitting method. The synthesis procedure of the materials and the extraction conditions (such as the composition of loading buffer and eluent) were optimized. Benefitting from the high surface area (545-804 m2 g-1), multiple functional framework and good porosity, the phosphonic acid-functionalized porous organic polymers showed a high adsorption rate and high adsorption capacity for β-agonists (224 mg g-1 and 171 mg g-1 for clenbuterol and ractopamine, respectively). The analytes were quantified by ultra-high-performance liquid chromatography coupled to high-resolution tandem mass spectrometry. It showed a good linearity (with R 2 ranging from 0.9950 to 0.9991 in the linear range of 3-5 orders of magnitude), with low limits of quantification ranging from 0.05 to 0.25 ng g-1. The limits of detection of the method for the analytes were measured to be in the range of 0.02 to 0.1 ng g-1. The recoveries of target analytes from real samples on the material were in the range of 62.4-119.4% with relative standard deviations of 0.6-12.1% (n = 4). Moreover, good reproducibility of the method was obtained with the interday RSD being lower than 11.7% (n = 5) and intraday RSD lower than 12.2% (n = 4). The proposed method was accurate, reliable and convenient for the simultaneous analysis of multiple β-agonists and β-blockers. Finally, the method was successfully applied for the analysis of such compounds in milk samples. This journal is © The Royal Society of Chemistry.Entities:
Year: 2021 PMID: 35478535 PMCID: PMC9038154 DOI: 10.1039/d1ra04481h
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Schematic of the preparation of PPOPs.
Elemental content (P), porosity and BET surface area of prepared materials
| Materials | PPA/toluene (mol mol−1) | P content (mmol g−1) | BET surface area (m2 g−1) | Pore volume (cm3 g−1) | Average pore diameter (nm) |
|---|---|---|---|---|---|
| POP10 | 1/9 | 0.233 | 784.900 | 0.609 | 3.102 |
| POP20 | 1/4 | 0.252 | 789.414 | 0.607 | 3.077 |
| POP40 | 2/3 | 1.479 | 804.127 | 0.705 | 3.508 |
| POP60 | 3/2 | 2.116 | 728.048 | 0.582 | 3.197 |
| POP80 | 4/1 | 2.695 | 545.085 | 0.473 | 3.472 |
Fig. 2(a) N2 sorption–desorption isotherms and (b) pore diameter distributions of PPOPs; (c) solid-state 13C NMR spectrum of POP20 and (d) TGA curve of POP20.
Fig. 4(a) Effect of TCA concentration in loading buffer on the extraction efficiency of analytes; (b) effect of ACN content in loading buffer on the extraction efficiency; (c) effect of salt concentration in loading buffer on the extraction efficiency; (d) effect of eluent type on the extraction efficiency (ε is the dielectric constant).
Fig. 3Effect of different PPOPs of on the extraction performance of β-agonists and β-blockers under identical conditions.
Fig. 5Adsorption isotherms of (a) clenbuterol and (b) ractopamine onto POP20, and the linear regression by fitting the equilibrium adsorption data with the Langmuir adsorption model.
Fig. 6Adsorption curves of analytes onto POP20 versus contact time in aqueous solution, and the insets of the figure show the pseudo-second-order kinetic plot for the adsorption (analytes concentration: 1000 mg L−1): (a) clenbuterol and (b) ractopamine.
Analyte recovery and RSD of β-agonists and β-blockers spiked in milk at three concentrations (n = 4)
| Compound | Spiked (0.5 ng g−1) | Spiked (1.0 ng g−1) | Spiked (5.0 ng g−1) | ||||
|---|---|---|---|---|---|---|---|
| Recovery (%) | RSD (%) | Recovery (%) | RSD (%) | Recovery (%) | RSD (%) | ||
| β-Agonists | Ractopamine | 106.8 | 5.1 | 101.4 | 1.3 | 97.4 | 3.1 |
| Salbutamol | 117.1 | 2.1 | 119.2 | 1.1 | 110.9 | 8.2 | |
| Terbutaline | 97.1 | 4.5 | 102.2 | 5.2 | 89.4 | 12.1 | |
| Cimaterol | 96.3 | 9.8 | 84.6 | 5.7 | 89.4 | 5.3 | |
| Clenbuterol | 107.3 | 3.5 | 112.5 | 1.2 | 110.5 | 2.3 | |
| Tulobuterol | 83.2 | 8.1 | 80.3 | 3.6 | 116.6 | 3.5 | |
| Clorprenaline | 85.1 | 11.1 | 98.6 | 7.3 | 83.4 | 2.3 | |
| Cimbuterol | 103.6 | 4.2 | 85.4 | 8.3 | 80.8 | 0.6 | |
| Brombuterol | 80.3 | 2.7 | 84.3 | 1.9 | 87.9 | 7.1 | |
| Mabuterol | 112.4 | 3.0 | 112.9 | 1.6 | 111.8 | 2.8 | |
| β-Blockers | Nadolol | 89.1 | 3.3 | 82.0 | 2.2 | 83.1 | 4.1 |
| Atenolol | 62.4 | 2.6 | 69.2 | 2.7 | 67.7 | 0.6 | |
| Sotalol | 112.9 | 8.3 | 109.8 | 4.0 | 101.0 | 5.3 | |
| Betaxolol | 110.6 | 5.7 | 119.4 | 1.0 | 110.6 | 2.7 | |
| Propranolol | 88.8 | 5.4 | 73.9 | 3.2 | 68.5 | 7.2 | |